We conclude that targeting I2PP2A can improve tau pathologies and memory deficits in human tau transgenic mice, and activation of PKA contributes to GSK-3β inhibition induced by silencing I2PP2Ain vitro, suggesting that I2PP2A is a promising multiple target of AD. Here, MAPT is linked to Alzheimer disease.